Advertisement
The company expects to announce its first quarter 2008 final financialresults on May 2, 2008. At that time, the company also expects to revise itsannual guidance for 2008. In the interim, the company is withdrawing thefirst quarter and full-year 2008 earnings and revenue guidance previouslyprovided on January 7, 2008.
Advertisement
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to improving the livesof patients with vascular disease through the development of innovativeendovascular therapies. ev3's products are used by endovascular specialiststo treat a wide range of peripheral vascular and neurovascular diseases anddisorders. The company offers a comprehensive portfolio of treatment options,including the primary interventional technologies used today -- peripheralangioplasty balloons, stents, plaque excision systems, embolic protectiondevices, liquid embolics, embolization coils, thrombectomy catheters andocclusion balloons. More information about the company and its products canbe found at http://www.ev3.net.
ev3, the ev3 logo, and FoxHollow are trademarks of ev3 Inc., registered inthe U.S. and other countries.
Forward Looking Statements
Statements contained in this press release that are not historicalinformation are forward-looking statements as defined within the PrivateSecurities Litigation Reform Act of 1995. Such statements include, but are notlimited to, statements about future financial and operating results,anticipated revenue synergies and cost savings as a result of ev3's mergerwith FoxHollow and the timing thereof, anticipated expenses as a result ofev3's merger with FoxHollow and the timing thereof, effects of recent U.S.peripheral vascular sales force restructuring activities, new product benefitsand market acceptance, anticipated costs and expenses paid in connection withoutstanding litigation and other statements identified by words such as"expect," "anticipate," "will," "may," "believe," "could," "outlook,""guidance," or words of similar meaning and any other statements that are nothistorical facts. Such forward-looking statements are based upon the currentbeliefs and expectations of ev3's management and are inherently subject torisks and uncertainties that could cause actual results to differ materiallyfrom those projected or implied. Such potential risks and uncertaintiesinclude, but are not limited to, in no particular order: the failure torealize revenue synergies and cost-savings from ev3's merger with FoxHollow ordelay in realization thereof; the businesses of ev3 and FoxHollow not beingintegrated successfully, or such integration taking longer or being moredifficult, time-consuming or costly to accomplish than expected; the impact ofcompetitive products and pricing; changes in the regulatory environment;availability of third party reimbursement; potential margin pressure resultingfrom volume selling, as well as potential adverse effects on future productdemand resulting from volume purchases; delays in regulatory approvals and theintroduction of new products; market acceptance of new products and success
